Published in J Neurochem on December 20, 2005
Alternative splicing and disease. Biochim Biophys Acta (2008) 3.47
Global analysis of alternative splicing during T-cell activation. RNA (2007) 2.11
Expression of the splicing factor gene SFRS10 is reduced in human obesity and contributes to enhanced lipogenesis. Cell Metab (2011) 2.08
Global profiling and molecular characterization of alternative splicing events misregulated in lung cancer. Mol Cell Biol (2010) 1.53
A genomic screen for activators of the antioxidant response element. Proc Natl Acad Sci U S A (2007) 1.44
Tau exon 10 alternative splicing and tauopathies. Mol Neurodegener (2008) 1.38
Kinase domain insertions define distinct roles of CLK kinases in SR protein phosphorylation. Structure (2009) 1.36
Analysis of alternative splicing associated with aging and neurodegeneration in the human brain. Genome Res (2011) 1.35
Tau-based treatment strategies in neurodegenerative diseases. Neurotherapeutics (2008) 1.13
RNA helicase p68 (DDX5) regulates tau exon 10 splicing by modulating a stem-loop structure at the 5' splice site. Mol Cell Biol (2011) 1.12
Antisense oligonucleotides: treating neurodegeneration at the level of RNA. Neurotherapeutics (2013) 1.10
Evaluation of substituted 6-arylquinazolin-4-amines as potent and selective inhibitors of cdc2-like kinases (Clk). Bioorg Med Chem Lett (2009) 1.06
Differential incorporation of tau isoforms in Alzheimer's disease. J Alzheimers Dis (2008) 1.04
SR protein 9G8 modulates splicing of tau exon 10 via its proximal downstream intron, a clustering region for frontotemporal dementia mutations. Mol Cell Neurosci (2006) 1.04
Phosphorylation-mediated regulation of alternative splicing in cancer. Int J Cell Biol (2013) 1.00
Rapid generation of splicing reporters with pSpliceExpress. Gene (2008) 0.99
Variation in tau isoform expression in different brain regions and disease states. Neurobiol Aging (2013) 0.94
Tau splicing and the intricacies of dementia. J Cell Physiol (2012) 0.94
Tau as a biomarker of neurodegenerative diseases. Biomark Med (2008) 0.91
Alternative splicing of exon 10 in the tau gene as a target for treatment of tauopathies. BMC Neurosci (2008) 0.89
MicroRNAs and the Regulation of Tau Metabolism. Int J Alzheimers Dis (2012) 0.89
Cyclic AMP-dependent protein kinase regulates the alternative splicing of tau exon 10: a mechanism involved in tau pathology of Alzheimer disease. J Biol Chem (2011) 0.89
Brain pathology in myotonic dystrophy: when tauopathy meets spliceopathy and RNAopathy. Front Mol Neurosci (2014) 0.87
PSF suppresses tau exon 10 inclusion by interacting with a stem-loop structure downstream of exon 10. J Mol Neurosci (2011) 0.87
Hsp70 alters tau function and aggregation in an isoform specific manner. Biochemistry (2012) 0.87
N-terminus of the protein kinase CLK1 induces SR protein hyperphosphorylation. Biochem J (2014) 0.86
Tra2-mediated recognition of HIV-1 5' splice site D3 as a key factor in the processing of vpr mRNA. J Virol (2012) 0.86
Alternative ion channel splicing in mesial temporal lobe epilepsy and Alzheimer's disease. Genome Biol (2007) 0.86
An SRp75/hnRNPG complex interacting with hnRNPE2 regulates the 5' splice site of tau exon 10, whose misregulation causes frontotemporal dementia. Gene (2011) 0.85
Human Tra2 proteins jointly control a CHEK1 splicing switch among alternative and constitutive target exons. Nat Commun (2014) 0.82
DARPP-32 binds to tra2-beta1 and influences alternative splicing. Biochim Biophys Acta (2010) 0.82
Truncation and Activation of Dual Specificity Tyrosine Phosphorylation-regulated Kinase 1A by Calpain I: A MOLECULAR MECHANISM LINKED TO TAU PATHOLOGY IN ALZHEIMER DISEASE. J Biol Chem (2015) 0.82
Bioactive marine drugs and marine biomaterials for brain diseases. Mar Drugs (2014) 0.81
Characterization of nuclear localization signals (NLSs) and function of NLSs and phosphorylation of serine residues in subcellular and subnuclear localization of transformer-2β (Tra2β). J Biol Chem (2013) 0.81
Splicing kinase SRPK1 conforms to the landscape of its SR protein substrate. Biochemistry (2013) 0.79
Transformer 2β homolog (Drosophila) (TRA2B) regulates protein kinase C δI (PKCδI) splice variant expression during 3T3L1 preadipocyte cell cycle. J Biol Chem (2014) 0.79
Neuronal-specific deficiency of the splicing factor Tra2b causes apoptosis in neurogenic areas of the developing mouse brain. PLoS One (2014) 0.78
Benzobisthiazoles Represent a Novel Scaffold for Kinase Inhibitors of CLK Family Members. Biochemistry (2016) 0.77
The Ambiguous Relationship of Oxidative Stress, Tau Hyperphosphorylation, and Autophagy Dysfunction in Alzheimer's Disease. Oxid Med Cell Longev (2015) 0.77
Splicing factor transformer-2β (Tra2β) regulates the expression of regulator of G protein signaling 4 (RGS4) gene and is induced by morphine. PLoS One (2013) 0.76
Intra-domain Cross-talk Regulates Serine-arginine Protein Kinase 1-dependent Phosphorylation and Splicing Function of Transformer 2β1. J Biol Chem (2015) 0.76
Identification of potential cancer-related pseudogenes in lung adenocarcinoma based on ceRNA hypothesis. Oncotarget (2017) 0.75
Large recurrent microdeletions associated with schizophrenia. Nature (2008) 20.25
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet (2009) 15.15
Identification of loci associated with schizophrenia by genome-wide association and follow-up. Nat Genet (2008) 10.52
Common variants conferring risk of schizophrenia. Nature (2009) 10.37
Mild cognitive impairment. Lancet (2006) 10.21
Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med (2012) 10.16
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol (2010) 8.74
Meta-analysis and imputation refines the association of 15q25 with smoking quantity. Nat Genet (2010) 8.55
Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet (2013) 8.02
Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nat Genet (2013) 7.44
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA (2009) 7.29
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol (2010) 6.55
Sequence variants at CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior. Nat Genet (2010) 6.49
CSF markers for incipient Alzheimer's disease. Lancet Neurol (2003) 6.12
Function of alternative splicing. Gene (2004) 5.95
Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci (2004) 5.37
A genome-wide investigation of SNPs and CNVs in schizophrenia. PLoS Genet (2009) 5.01
Classifying brain states and determining the discriminating activation patterns: Support Vector Machine on functional MRI data. Neuroimage (2005) 4.83
Disruption of the neurexin 1 gene is associated with schizophrenia. Hum Mol Genet (2008) 4.78
The snoRNA HBII-52 regulates alternative splicing of the serotonin receptor 2C. Science (2005) 4.54
Sequence and analysis of rice chromosome 4. Nature (2002) 4.39
Genome-wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. Nat Genet (2009) 4.38
Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging (2009) 4.36
CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain (2006) 3.95
Multiple independent loci at chromosome 15q25.1 affect smoking quantity: a meta-analysis and comparison with lung cancer and COPD. PLoS Genet (2010) 3.91
Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol (2014) 3.75
Identification of common variants associated with human hippocampal and intracranial volumes. Nat Genet (2012) 3.73
Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol (2009) 3.65
ASD: a bioinformatics resource on alternative splicing. Nucleic Acids Res (2006) 3.60
PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease. Sci Transl Med (2010) 3.48
Alternative splicing and disease. Biochim Biophys Acta (2008) 3.47
ASD: the Alternative Splicing Database. Nucleic Acids Res (2004) 3.26
Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease. Neurobiol Aging (2003) 2.96
A comprehensive family-based replication study of schizophrenia genes. JAMA Psychiatry (2013) 2.93
Improved detection of common variants associated with schizophrenia and bipolar disorder using pleiotropy-informed conditional false discovery rate. PLoS Genet (2013) 2.68
Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. PLoS One (2010) 2.57
A primate-specific, brain isoform of KCNH2 affects cortical physiology, cognition, neuronal repolarization and risk of schizophrenia. Nat Med (2009) 2.37
Focal decline of cortical thickness in Alzheimer's disease identified by computational neuroanatomy. Cereb Cortex (2004) 2.36
Higher glucose levels associated with lower memory and reduced hippocampal microstructure. Neurology (2013) 2.33
Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance. Neurobiol Aging (2010) 2.27
Neurexin 1 (NRXN1) deletions in schizophrenia. Schizophr Bull (2009) 2.25
Human tra2-beta1 autoregulates its protein concentration by influencing alternative splicing of its pre-mRNA. Hum Mol Genet (2004) 2.23
CD36, a class B scavenger receptor, is expressed on microglia in Alzheimer's disease brains and can mediate production of reactive oxygen species in response to beta-amyloid fibrils. Am J Pathol (2002) 2.22
Common variants at VRK2 and TCF4 conferring risk of schizophrenia. Hum Mol Genet (2011) 2.21
Automated cortical thickness measurements from MRI can accurately separate Alzheimer's patients from normal elderly controls. Neurobiol Aging (2006) 2.09
Expression of the splicing factor gene SFRS10 is reduced in human obesity and contributes to enhanced lipogenesis. Cell Metab (2011) 2.08
Multivariate deformation-based analysis of brain atrophy to predict Alzheimer's disease in mild cognitive impairment. Neuroimage (2007) 2.03
Measurement of basal forebrain atrophy in Alzheimer's disease using MRI. Brain (2005) 2.03
Function of alternative splicing. Gene (2012) 2.00
Measurement of alpha- and beta-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients. Exp Neurol (2003) 1.99
Gene variants associated with schizophrenia in a Norwegian genome-wide study are replicated in a large European cohort. J Psychiatr Res (2010) 1.98
Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease. Hum Mol Genet (2003) 1.98
Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. Alzheimers Dement (2013) 1.98
Improved detection of common variants associated with schizophrenia by leveraging pleiotropy with cardiovascular-disease risk factors. Am J Hum Genet (2013) 1.96
Maternally derived microduplications at 15q11-q13: implication of imprinted genes in psychotic illness. Am J Psychiatry (2011) 1.94
Consensus paper of the WFSBP Task Force on Biological Markers: biological markers in depression. World J Biol Psychiatry (2007) 1.93
Pre-mRNA secondary structures influence exon recognition. PLoS Genet (2007) 1.92
The ENIGMA Consortium: large-scale collaborative analyses of neuroimaging and genetic data. Brain Imaging Behav (2014) 1.90
Gene expression profiles in anatomically and functionally distinct regions of the normal aged human brain. Physiol Genomics (2006) 1.88
Common variants on 8p12 and 1q24.2 confer risk of schizophrenia. Nat Genet (2011) 1.88
Phosphorylation of tau by fyn: implications for Alzheimer's disease. J Neurosci (2004) 1.88
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement (2011) 1.87
Genomic convergence: identifying candidate genes for Parkinson's disease by combining serial analysis of gene expression and genetic linkage. Hum Mol Genet (2003) 1.84
The snoRNA MBII-52 (SNORD 115) is processed into smaller RNAs and regulates alternative splicing. Hum Mol Genet (2010) 1.83
Genomewide association analysis followed by a replication study implicates a novel candidate gene for neuroticism. Arch Gen Psychiatry (2008) 1.75
Factor structure and external validity of the PANSS revisited. Schizophr Res (2005) 1.74
Grey matter correlates of clinical variables in amyotrophic lateral sclerosis (ALS): a neuroimaging study of ALS motor phenotype heterogeneity and cortical focality. J Neurol Neurosurg Psychiatry (2012) 1.70
Tau protects microtubules in the axon from severing by katanin. J Neurosci (2006) 1.69
Penetrance for copy number variants associated with schizophrenia. Hum Mol Genet (2010) 1.64
Schizophrenia: from the brain to peripheral markers. A consensus paper of the WFSBP task force on biological markers. World J Biol Psychiatry (2009) 1.64
Cognitive impairment in 873 patients with idiopathic Parkinson's disease. Results from the German Study on Epidemiology of Parkinson's Disease with Dementia (GEPAD). J Neurol (2008) 1.62
Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. PLoS One (2010) 1.62
White matter damage in Alzheimer disease and mild cognitive impairment: assessment with diffusion-tensor MR imaging and parallel imaging techniques. Radiology (2007) 1.61
Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease. Alzheimers Dement (2011) 1.59
Ganglioside-induced differentiation-associated protein-1 is mutant in Charcot-Marie-Tooth disease type 4A/8q21. Nat Genet (2001) 1.59
A pharmacological model for psychosis based on N-methyl-D-aspartate receptor hypofunction: molecular, cellular, functional and behavioral abnormalities. Biol Psychiatry (2006) 1.57
Body mass index is associated with biological CSF markers of core brain pathology of Alzheimer's disease. Neurobiol Aging (2011) 1.57
IFATS collection: The conditioned media of adipose stromal cells protect against hypoxia-ischemia-induced brain damage in neonatal rats. Stem Cells (2009) 1.57
Preferential loss of myelin-associated glycoprotein reflects hypoxia-like white matter damage in stroke and inflammatory brain diseases. J Neuropathol Exp Neurol (2003) 1.55
Automated detection of brain atrophy patterns based on MRI for the prediction of Alzheimer's disease. Neuroimage (2009) 1.55
Dopamine transporter imaging in autopsy-confirmed Parkinson's disease and multiple system atrophy. Mov Disord (2011) 1.53
Multivariate network analysis of fiber tract integrity in Alzheimer's disease. Neuroimage (2006) 1.52
Management of a twenty-first century brain bank: experience in the BrainNet Europe consortium. Acta Neuropathol (2008) 1.51
Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia. Trends Neurosci (2011) 1.51
Interplay between DISC1 and GABA signaling regulates neurogenesis in mice and risk for schizophrenia. Cell (2012) 1.48
The role of the major histocompatibility complex region in cognition and brain structure: a schizophrenia GWAS follow-up. Am J Psychiatry (2013) 1.48
Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. Biomark Med (2012) 1.48
Heterogeneity in age-related white matter changes. Acta Neuropathol (2011) 1.47
Psychosis susceptibility gene ZNF804A and cognitive performance in schizophrenia. Arch Gen Psychiatry (2010) 1.46